471 related articles for article (PubMed ID: 30496802)
21. Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL.
Li L; Zhang X; Zhang T; Song Z; Hu G; Li W; Li L; Qiu L; Qian Z; Zhou S; Liu X; Feng L; Pan Y; Zhai Q; Meng B; Ren X; Fu K; Wang P; Wang X; Zhang H
Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e381-e389. PubMed ID: 29983382
[TBL] [Abstract][Full Text] [Related]
22. c-MYC and p53 expression highlight starry-sky pattern as a favourable prognostic feature in R-CHOP-treated diffuse large B-cell lymphoma.
Bouroumeau A; Bussot L; Bonnefoix T; Fournier C; Chapusot C; Casasnovas O; Martin L; McLeer A; Col E; David-Boudet L; Lefebvre C; Algrin C; Raskovalova T; Jacob MC; Vettier C; Chevalier S; Callanan MB; Gressin R; Emadali A; Sartelet H
J Pathol Clin Res; 2021 Nov; 7(6):604-615. PubMed ID: 34374220
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Green TM; Young KH; Visco C; Xu-Monette ZY; Orazi A; Go RS; Nielsen O; Gadeberg OV; Mourits-Andersen T; Frederiksen M; Pedersen LM; Møller MB
J Clin Oncol; 2012 Oct; 30(28):3460-7. PubMed ID: 22665537
[TBL] [Abstract][Full Text] [Related]
24. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab.
Barrans S; Crouch S; Smith A; Turner K; Owen R; Patmore R; Roman E; Jack A
J Clin Oncol; 2010 Jul; 28(20):3360-5. PubMed ID: 20498406
[TBL] [Abstract][Full Text] [Related]
25. MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab.
Perry AM; Alvarado-Bernal Y; Laurini JA; Smith LM; Slack GW; Tan KL; Sehn LH; Fu K; Aoun P; Greiner TC; Chan WC; Bierman PJ; Bociek RG; Armitage JO; Vose JM; Gascoyne RD; Weisenburger DD
Br J Haematol; 2014 May; 165(3):382-91. PubMed ID: 24506200
[TBL] [Abstract][Full Text] [Related]
26. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.
Copie-Bergman C; Cuillière-Dartigues P; Baia M; Briere J; Delarue R; Canioni D; Salles G; Parrens M; Belhadj K; Fabiani B; Recher C; Petrella T; Ketterer N; Peyrade F; Haioun C; Nagel I; Siebert R; Jardin F; Leroy K; Jais JP; Tilly H; Molina TJ; Gaulard P
Blood; 2015 Nov; 126(22):2466-74. PubMed ID: 26373676
[TBL] [Abstract][Full Text] [Related]
27. [Significance of myc gene rearrangement and its correlation with prognosis in diffuse large B cell lymphoma].
Zhang HW; Chen ZW; He JX; Zheng YP; Han WE; Zhao ZQ; Bai W; Wang JF
Zhonghua Zhong Liu Za Zhi; 2013 Feb; 35(2):119-23. PubMed ID: 23714666
[TBL] [Abstract][Full Text] [Related]
28. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
[TBL] [Abstract][Full Text] [Related]
29. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.
Johnson NA; Slack GW; Savage KJ; Connors JM; Ben-Neriah S; Rogic S; Scott DW; Tan KL; Steidl C; Sehn LH; Chan WC; Iqbal J; Meyer PN; Lenz G; Wright G; Rimsza LM; Valentino C; Brunhoeber P; Grogan TM; Braziel RM; Cook JR; Tubbs RR; Weisenburger DD; Campo E; Rosenwald A; Ott G; Delabie J; Holcroft C; Jaffe ES; Staudt LM; Gascoyne RD
J Clin Oncol; 2012 Oct; 30(28):3452-9. PubMed ID: 22851565
[TBL] [Abstract][Full Text] [Related]
30. Patterns of Failure in Patients With Double Hit or Double Expressor Lymphomas: Implications for Radiation Therapy.
Tumati V; Trivedi L; Li HC; Patel P; Scaglioni PP; Vusirikala M; Sadeghi N; Rizvi S; Chen W; Wachsmann J; Collins R; Desai NB
Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1126-1132. PubMed ID: 29722657
[TBL] [Abstract][Full Text] [Related]
31. Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.
Sermer D; Bobillo S; Dogan A; Zhang Y; Seshan V; Lavery JA; Batlevi C; Caron P; Hamilton A; Hamlin P; Horwitz S; Joffe E; Kumar A; Matasar M; Noy A; Owens C; Moskowitz A; Palomba ML; Straus D; von Keudell G; Rodriguez-Rivera I; Falchi L; Zelenetz A; Yahalom J; Younes A
Blood Adv; 2020 Jul; 4(14):3382-3390. PubMed ID: 32722781
[TBL] [Abstract][Full Text] [Related]
32. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma.
Xu J; Oki Y; Saksena A; Desai P; Lin P; Tang G; Yin CC; You MJ; Thakral B; Medeiros LJ; Li S
Hum Pathol; 2017 Feb; 60():160-166. PubMed ID: 27816715
[TBL] [Abstract][Full Text] [Related]
33. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
Horn H; Ziepert M; Becher C; Barth TF; Bernd HW; Feller AC; Klapper W; Hummel M; Stein H; Hansmann ML; Schmelter C; Möller P; Cogliatti S; Pfreundschuh M; Schmitz N; Trümper L; Siebert R; Loeffler M; Rosenwald A; Ott G;
Blood; 2013 Mar; 121(12):2253-63. PubMed ID: 23335369
[TBL] [Abstract][Full Text] [Related]
34. Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell-like diffuse large B-cell lymphoma.
Chen J; Xu-Monette ZY; Deng L; Shen Q; Manyam GC; Martinez-Lopez A; Zhang L; Montes-Moreno S; Visco C; Tzankov A; Yin L; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Huh J; Ponzoni M; Ferreri AJ; Zhao X; Møller MB; Farnen JP; Winter JN; Piris MA; Pham L; Young KH
Oncotarget; 2015 Mar; 6(8):5597-614. PubMed ID: 25704881
[TBL] [Abstract][Full Text] [Related]
35. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.
Savage KJ; Johnson NA; Ben-Neriah S; Connors JM; Sehn LH; Farinha P; Horsman DE; Gascoyne RD
Blood; 2009 Oct; 114(17):3533-7. PubMed ID: 19704118
[TBL] [Abstract][Full Text] [Related]
36. MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.
Li S; Desai P; Lin P; Yin CC; Tang G; Wang XJ; Konoplev SN; Khoury JD; Bueso-Ramos CE; Medeiros LJ
Histopathology; 2016 Jun; 68(7):1090-8. PubMed ID: 26426741
[TBL] [Abstract][Full Text] [Related]
37. Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Tzankov A; Xu-Monette ZY; Gerhard M; Visco C; Dirnhofer S; Gisin N; Dybkaer K; Orazi A; Bhagat G; Richards KL; Hsi ED; Choi WW; van Krieken JH; Ponzoni M; Ferreri AJ; Ye Q; Winter JN; Farnen JP; Piris MA; Møller MB; You MJ; McDonnell T; Medeiros LJ; Young KH
Mod Pathol; 2014 Jul; 27(7):958-71. PubMed ID: 24336156
[TBL] [Abstract][Full Text] [Related]
38. [B-cell lymphomas with concurrent myc and bcl-2/IgH or bcl-6 translocations].
Luo DL; Liu YH; Zhang F; Xu FP; Yan LX; Chen J; Xu J; Luo XL; Zhuang HG
Zhonghua Bing Li Xue Za Zhi; 2013 Sep; 42(9):584-8. PubMed ID: 24314242
[TBL] [Abstract][Full Text] [Related]
39. Aggressive B cell Lymphoma: Optimal Therapy for MYC-positive, Double-Hit, and Triple-Hit DLBCL.
Dunleavy K
Curr Treat Options Oncol; 2015 Dec; 16(12):58. PubMed ID: 26634708
[TBL] [Abstract][Full Text] [Related]
40. Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study.
Visco C; Tzankov A; Xu-Monette ZY; Miranda RN; Tai YC; Li Y; Liu WM; d'Amore ES; Li Y; Montes-Moreno S; Dybkær K; Chiu A; Orazi A; Zu Y; Bhagat G; Wang HY; Dunphy CH; His ED; Zhao XF; Choi WW; Zhao X; van Krieken JH; Huang Q; Ai W; O'Neill S; Ponzoni M; Ferreri AJ; Kahl BS; Winter JN; Go RS; Dirnhofer S; Piris MA; Møller MB; Wu L; Medeiros LJ; Young KH
Haematologica; 2013 Feb; 98(2):255-63. PubMed ID: 22929980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
